Cytokines, Chemokines & Receptors

Cat. No.

AT0652

CAS No.

1007223-17-7

Olokizumab

Synonyms: CDP 6038; OKZ

Olokizumab (CDP 6038) is a humanized monoclonal antibody designed to specifically target interleukin-6 (IL-6), a cytokine implicated in the inflammatory response associated with rheumatoid arthritis (RA). This antibody is utilized primarily in the study of inflammatory mechanisms and potential therapeutic interventions for RA. Its specificity for IL-6 makes it a valuable tool in the elucidation of cytokine-driven pathways in disease pathology and in the assessment of novel anti-inflammatory strategies.

Cat. No.

AT0654

CAS No.

2761187-73-7

Turenkibart

Turenkibart is a human monoclonal antibody of the IgG1κ subtype that specifically targets IL17A. For experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0676

CAS No.

2921564-55-6

Adezkibart

Adezkibart is a human monoclonal antibody developed as an immunosuppressant, specifically targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Produced in the Chinese hamster ovary (CHO) cell line CHO-K1, this antibody binds selectively to FLT3LG, effectively blocking the associated signaling pathway. By inhibiting this pathway, Adezkibart reduces the immune response and demonstrates potent immunosuppressive effects. This antibody is particularly valuable for research into immune-related diseases, offering insights into immune regulation and potential therapeutic targets.

Cat. No.

AT0678

CAS No.

2837169-12-5

Azirkitug

Azirkitug is a humanized IgG1κ monoclonal antibody specifically targeting CCR8. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Cat. No.

AT0679

CAS No.

2458202-06-5

Vilamakitug

Synonyms: XB-2001

Vilamakitug (XB-2001) is a human IgG4 κ monoclonal antibody specifically targeting IL-1α. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cat. No.

AT0682

Anti-CTLA-8/IL-17a Antibody

Cat. No.

AT0691

CAS No.

2988741-17-7

Velaprumig

Velaprumig is a monoclonal antibody engineered to target human CD99, CCL25, and Aβ-47F, a specific epitope of the amyloid beta peptide. This antibody plays a crucial role in regulating immune cell migration and attenuating pathological processes associated with β-amyloid deposition. Its dual action not only serves as an immunomodulator but also offers potential therapeutic benefits in the treatment of Alzheimer’s disease by targeting key mechanisms implicated in its pathogenesis. Velaprumig is suitable for a range of research applications focused on the study of immune response and neurodegenerative diseases.

Cat. No.

AT0704

CAS No.

2734715-10-5

Stapokibart

Synonyms: CM310

Stapokibart (CM310) is a humanized monoclonal antibody specifically designed to target IL-4Rα, effectively inhibiting the binding of cytokines IL-4 and IL-13 to their co-receptor subunit IL-4Rα. This antibody demonstrates cross-species reactivity, interacting with IL-4Rα in humans, cynomolgus monkeys, and rats, making it a versatile tool for diverse biological research settings.

Cat. No.

AT0724

CAS No.

1159266-37-1

Mogamulizumab

Synonyms: KW-0761

Mogamulizumab (KW-0761) is a recombinant monoclonal antibody that targets CC chemokine receptor 4 (CCR4). This antibody facilitates the elimination of tumor cells through antibody-dependent cellular cytotoxicity (ADCC), a critical mechanism for immune-mediated tumor cell eradication. Mogamulizumab is primarily utilized in the investigation of various cancers, including adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), providing a valuable tool for research in oncology and immunotherapy.

Cat. No.

AT0729

CAS No.

2833673-47-3

Comekibart

Comekibart is a humanized IgG4κ monoclonal antibody specifically targeting the IL4 receptor (IL4R). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and isotype matching ensure accurate and reliable results in research applications focusing on the modulation and study of IL4R-mediated signaling pathways.

Cat. No.

AT0736

MEDI-2045

MEDI-2045 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-4Ra/CD124. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT0746

REGN-7257

REGN-7257 is a humanized monoclonal antibody designed to specifically target IL2RG, effectively inhibiting the signaling pathways of all γ-c cytokines. This antibody is particularly useful in research focused on aplastic anemia. For experimental control purposes, the recommended isotype control is Human IgG4 kappa.

Cat. No.

AT0748

CAS No.

914613-48-2

Canakinumab

Synonyms: Ilaris; ACZ 885

Canakinumab (ACZ885) is a recombinant human monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1β). Demonstrating potent inhibitory activity, canakinumab exhibits half-maximal inhibitory concentrations (IC50) of 43.6 pM for human IL-1β and 40.8 pM for marmoset IL-1β. Its primary mechanism involves the interruption of IL-1β signaling, effectively reducing inflammatory responses associated with autoimmune disorders. This antibody is pivotal for research focused on the pathophysiology and potential therapeutic interventions for inflammation-driven diseases.

Cat. No.

AT0751

CAS No.

1044511-01-4

Benralizumab

Synonyms: MEDI-563; BIW-8405

Benralizumab (MEDI-563) is a cytolytic monoclonal antibody that targets the interleukin-5 receptor α (IL-5Rα), facilitating direct, rapid, and near-complete depletion of eosinophils through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). This agent is specifically designed for the treatment of severe eosinophilic asthma, offering a targeted therapeutic approach by modulating the eosinophilic inflammatory response that characterizes this condition.

Cat. No.

AT0766

CAS No.

1167985-17-2

Ozoralizumab

Synonyms: ATN-103

Ozoralizumab (ATN-103) is a humanized trivalent nanobody that targets tumor necrosis factor alpha (TNFα). Comprising two anti-human TNFα nanobodies and one anti-human serum albumin (HSA) nanobody, this antibody is engineered for enhanced stability and serum half-life. It is particularly relevant for research into inflammatory disorders, including various forms of arthritis, where TNFα plays a pivotal role in pathogenesis.

Cat. No.

AT0767

CAS No.

1365659-05-7

Atrosab

Atrosab is a humanized IgG1 monoclonal antibody that functions as an antagonist to tumor necrosis factor receptor 1 (TNFR1). It effectively inhibits TNF-alpha-mediated apoptosis and the production of interleukins IL-6 and IL-8, key mediators in inflammatory processes. This antibody has been shown to reduce neurological deficits, highlighting its potential utility in the study of neuroinflammation and other inflammatory diseases. For control experiments, the recommended isotype control is Human IgG1 kappa.

Cat. No.

AT0770

CAS No.

1350289-85-8

Guselkumab

Synonyms: CNTO 1959

Guselkumab is a recombinant human IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). This antibody exhibits high affinity for IL-23, with dissociation constants (Kd) of 3.3 pmol/L for human IL-23 and 1.9 pmol/L for IL-23 derived from cynomolgus monkeys. By binding to the IL-23p19 subunit, Guselkumab effectively inhibits the production of cytokines that are downstream in the IL-23 signaling pathway. This mechanism of action makes Guselkumab particularly useful in the study of psoriatic arthritis, providing a valuable tool for research into the pathophysiology and potential treatment of this condition.

Cat. No.

AT0777

CAS No.

1610353-18-8

Brazikumab

Synonyms: AMG 139; MEDI2070

Brazikumab (AMG 139) is a human IgG2 monoclonal antibody designed to selectively target the p19 subunit of interleukin-23 (IL-23). It exhibits a high binding affinity with a dissociation constant (K_D) of 0.138 nM for human IL-23. This specificity makes Brazikumab a valuable tool for the study of immune-mediated inflammatory disorders, particularly Crohn's disease.

Cat. No.

AT0779

CAS No.

252662-47-8

Toralizumab

Synonyms: IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

Toralizumab (IDEC-131) is a humanized monoclonal antibody targeting CD40 ligand (CD154), composed of human gamma 1 heavy chains and kappa light chains. This antibody selectively binds to CD40L expressed on T cells, effectively inhibiting CD40-mediated signaling. As an immunosuppressive agent, Toralizumab is primarily investigated for its therapeutic potential in systemic lupus erythematosus (SLE) research.

Cat. No.

AT0803

CAS No.

468715-71-1

Elsilimomab

Synonyms: B-E8; Anti-IL-6 MAB B-E8

Elsilimomab (B-E8) is an IgG1 monoclonal antibody that targets interleukin-6 (IL-6), exhibiting a dissociation constant (KD) of 22 pM and an inhibitory concentration (IC50) of 1.4 nM. This antibody is utilized in research focused on multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA), providing a valuable tool for investigating the role of IL-6 in these conditions.

Cat. No.

AT0806

CAS No.

2628092-47-5

Tegoprubart

Tegoprubart is a monoclonal antibody specifically targeting the CD40 ligand (CD40L), an essential component of immune system costimulation. By inhibiting CD40L, Tegoprubart effectively diminishes both cellular and antibody-mediated immune responses, facilitating the creation of a more tolerant immune environment. This antibody has demonstrated significant in vivo efficacy in various transplantation animal models, underscoring its potential utility in immune modulation and transplant medicine.

Cat. No.

AT0819

CAS No.

2744320-12-3

Vamikibart

Vamikibart is a chimeric humanized monoclonal antibody of the IgG2κ isotype, specifically designed to target interleukin 6 (IL-6). This antibody is engineered for high specificity and affinity in neutralizing IL-6, a cytokine involved in various inflammatory and autoimmune processes. Vamikibart is suitable for use in research focused on the role of IL-6 in disease mechanisms and therapeutic interventions.

Cat. No.

AT0839

CAS No.

1796570-08-5

Netakimab

Netakimab is a monoclonal antibody targeting interleukin-17 (IL-17). This biologic is specifically designed for research applications related to ankylosing spondylitis, psoriatic arthritis, and moderate-to-severe plaque psoriasis. Netakimab's mechanism of action involves the inhibition of IL-17, a key cytokine involved in the inflammation and pathogenesis of various autoimmune disorders. This makes it a valuable tool for studies aiming to understand and potentially modulate immune responses in these conditions.

Cat. No.

AT0860

LY2525623

LY2525623 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-23 (IL-23). This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT0862

Anti-IL-13 Antibody (H2L6)

Synonyms: H2L6

Anti-IL-13 (H2L6) is a humanized monoclonal antibody specifically targeting interleukin-13 (IL-13). This antibody is designed for the precise detection and neutralization of IL-13, a key cytokine involved in inflammatory responses and allergic reactions. It is applicable for use in various immunological assays, including ELISA, Western blotting, and immunohistochemistry, making it a valuable tool for research in immunology and inflammation.